Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
The role of amyloid PET in imaging neurodegenerative disorders: a review
M Chapleau, L Iaccarino… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Imaging of amyloid deposition using PET has been available in research studies for 2
decades and has been approved for clinical use by the US Food and Drug Administration …
decades and has been approved for clinical use by the US Food and Drug Administration …
FDA approval of lecanemab: the real start of widespread amyloid PET use?—the EANM Neuroimaging Committee perspective
Lecanemab is a humanized IgG1 monoclonal antibody that targets protofibrils, a species of
soluble aggregated amyloidbeta (Aβ). The drug was approved by the US Food and Drug …
soluble aggregated amyloidbeta (Aβ). The drug was approved by the US Food and Drug …
Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: the AMYPAD-DPMS randomized clinical trial
Importance Amyloid positron emission tomography (PET) allows the direct assessment of
amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this …
amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this …
A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic …
IS van Maurik, HM Broulikova, A Mank… - Alzheimer's & …, 2023 - Wiley Online Library
Introduction We aim to study the effect of a more precise diagnosis, by means of amyloid
positron emission tomography (PET), on institutionalization, mortality, and health‐care costs …
positron emission tomography (PET), on institutionalization, mortality, and health‐care costs …
Amyloid PET imaging in clinical practice
MA Kolanko, Z Win, F Loreto, N Patel, C Carswell… - Practical …, 2020 - pn.bmj.com
Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain Aβ
deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is …
deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is …
Dementia risk communication. A user manual for Brain Health Services—part 3 of 6
LNC Visser, C Minguillon… - Alzheimer's Research & …, 2021 - Springer
Growing evidence suggests dementia incidence can be reduced through prevention
programs targeting risk factors. To accelerate the implementation of such prevention …
programs targeting risk factors. To accelerate the implementation of such prevention …
Molecular imaging approaches in dementia
The increasing prevalence of dementia worldwide places a high demand on healthcare
providers to perform a diagnostic work-up in relatively early stages of the disease, given that …
providers to perform a diagnostic work-up in relatively early stages of the disease, given that …
Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent
Purpose To investigate the sensitivity of visual read (VR) to detect early amyloid pathology
and the overall utility of regional VR. Methods [18 F] Flutemetamol PET images of 497 …
and the overall utility of regional VR. Methods [18 F] Flutemetamol PET images of 497 …